Nature:基因和环境共同诱导表观遗传程序,启动肿瘤发生 

2021-02-04 haibei MedSci原创

在胰腺前上皮细胞组织损伤后最迅速激活的因子中存在报警素细胞因子白细胞介素33,它再现了损伤与突变的Kras合作的效果,以释放早期肿瘤和肿瘤转化的表观遗传重塑程序。

已有的研究显示,组织损伤会增加癌症的风险,但是我们对于其背后的机制还不甚了解。在小鼠胰腺癌模型中,与组织损伤相关的胰腺炎与Kras癌基因的激活突变合作,可以显著加快早期肿瘤病变的形成,并最终引发腺癌。

最近,研究人员在Nature杂志发文,其在自体小鼠模型中,通过整合基因组学,单细胞染色质测定和时空控制的功能扰动,表明Kras突变和组织损伤的组合在胰腺上皮细胞中促进了一个独特的染色质状态,以区别于正常的细胞再生。

这种与癌症相关的表观遗传状态在胰腺损伤后48小时内出现,并涉及一个 "尖细胞到新生儿 "的染色质开关,有助于定义人类胰腺癌基因的早期失调。

在胰腺前上皮细胞组织损伤后最迅速激活的因子中存在报警素细胞因子白细胞介素33,它再现了损伤与突变的Kras合作的效果,以释放早期肿瘤和肿瘤转化的表观遗传重塑程序。

总的来说,该研究阐明了基因-环境的相互作用是如何迅速产生基因调控程序,决定早期肿瘤的转化,并提供了一个分子框架,来理解癌症启动中遗传和环境线索之间的相互作用

 

原始出处:

Direna Alonso-Curbelo et al. A gene–environment-induced epigenetic program initiates tumorigenesis. Nature (2021). 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1884957, encodeId=4485188495ed5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jul 04 11:27:12 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923926, encodeId=82dd92392634, content=已读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Tue Feb 09 18:12:55 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923408, encodeId=57c19234082c, content=高校博士科研团队,提供SCI论文科研服务,文章提供原始数据,作者审核文章内容及结果后投稿,可指定拟投杂志,文章接受后付款,前期不收任何费用。术业有专攻,期待与您的合作1615858451, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03f65442056, createdName=1615858451, createdTime=Sun Feb 07 09:43:36 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922786, encodeId=2fd6922e86f6, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>肿瘤相关研究是人类进步的见证!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201214/0a46e2191a5242699349a9874b62d33a/2efbcdab43d94c83b8335fe60762edd5.jpg, createdBy=20395444502, createdName=枢筋寰骨, createdTime=Thu Feb 04 14:42:30 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
    2021-07-04 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1884957, encodeId=4485188495ed5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jul 04 11:27:12 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923926, encodeId=82dd92392634, content=已读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Tue Feb 09 18:12:55 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923408, encodeId=57c19234082c, content=高校博士科研团队,提供SCI论文科研服务,文章提供原始数据,作者审核文章内容及结果后投稿,可指定拟投杂志,文章接受后付款,前期不收任何费用。术业有专攻,期待与您的合作1615858451, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03f65442056, createdName=1615858451, createdTime=Sun Feb 07 09:43:36 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922786, encodeId=2fd6922e86f6, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>肿瘤相关研究是人类进步的见证!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201214/0a46e2191a5242699349a9874b62d33a/2efbcdab43d94c83b8335fe60762edd5.jpg, createdBy=20395444502, createdName=枢筋寰骨, createdTime=Thu Feb 04 14:42:30 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
    2021-02-09 ms5000000518166734

    已读,受益匪浅

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1884957, encodeId=4485188495ed5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jul 04 11:27:12 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923926, encodeId=82dd92392634, content=已读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Tue Feb 09 18:12:55 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923408, encodeId=57c19234082c, content=高校博士科研团队,提供SCI论文科研服务,文章提供原始数据,作者审核文章内容及结果后投稿,可指定拟投杂志,文章接受后付款,前期不收任何费用。术业有专攻,期待与您的合作1615858451, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03f65442056, createdName=1615858451, createdTime=Sun Feb 07 09:43:36 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922786, encodeId=2fd6922e86f6, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>肿瘤相关研究是人类进步的见证!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201214/0a46e2191a5242699349a9874b62d33a/2efbcdab43d94c83b8335fe60762edd5.jpg, createdBy=20395444502, createdName=枢筋寰骨, createdTime=Thu Feb 04 14:42:30 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
    2021-02-07 1615858451

    高校博士科研团队,提供SCI论文科研服务,文章提供原始数据,作者审核文章内容及结果后投稿,可指定拟投杂志,文章接受后付款,前期不收任何费用。术业有专攻,期待与您的合作1615858451

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1884957, encodeId=4485188495ed5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jul 04 11:27:12 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923926, encodeId=82dd92392634, content=已读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Tue Feb 09 18:12:55 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923408, encodeId=57c19234082c, content=高校博士科研团队,提供SCI论文科研服务,文章提供原始数据,作者审核文章内容及结果后投稿,可指定拟投杂志,文章接受后付款,前期不收任何费用。术业有专攻,期待与您的合作1615858451, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03f65442056, createdName=1615858451, createdTime=Sun Feb 07 09:43:36 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922786, encodeId=2fd6922e86f6, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>肿瘤相关研究是人类进步的见证!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201214/0a46e2191a5242699349a9874b62d33a/2efbcdab43d94c83b8335fe60762edd5.jpg, createdBy=20395444502, createdName=枢筋寰骨, createdTime=Thu Feb 04 14:42:30 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
    2021-02-04 枢筋寰骨

    #肿瘤#肿瘤相关研究是人类进步的见证!

    0

相关资讯

J Immunother Cancer :开发新型溶瘤病毒平台,有效对抗致命癌症胰腺癌

胰腺癌(Pancreatic Cancer),是一种恶性程度很高,诊断和治疗都很困难的消化道恶性肿瘤,胰腺癌有多种亚型,其中90%为胰腺导管腺癌。

阿片类药物或是导致胰腺癌发病率升高的潜在原因

胰腺癌是当前恶性程度最高的肿瘤之一,被称为“癌症之王”。胰腺癌起病比较隐匿,80%以上的患者在确诊时已经是中晚期,五年生存率很低,到目前为止尚无治愈该病的方法。

Sci Rep:研究人员培养出新的胰腺肿瘤模型,为新药测试提供更多可能性

胰腺导管腺癌(PDAC)预后不良的原因是间质纤维化严重,且多细胞微环境复杂,临床前模型难以完全重现。研究人员旨在开发一个完整的能维持生存、拥有三维多细胞结构和且能提供微环境线索的组织离体外植体模型,来

FDA授予Zenocutuzumab治疗NRG1基因融合肿瘤的“快速通道资格”

肿瘤学公司Merus今天宣布,美国食品药品监督管理局(FDA)已授予Zenocutuzumab(Zeno)治疗具有NRG1基因融合的转移性实体瘤患者的“快速通道资格”。

ESMO Open:致病性BRCA1/2胚系突变在胰腺癌患者中的发生率

胚系BRCA1/2致病性突变(gBRCApv)可增加胰腺癌的风险,并预测对铂类药物和聚(ADP-核糖)聚合酶(PARP)抑制剂的反应

Gastroenterology:ZEB1和YAP1锌依赖性的共激活调控在胰腺癌转移中的重要作用

胰腺癌是目前死亡率最高的癌症之一,具有广泛转移的特点,绝大部分患者在确诊时已是晚期。上皮间质转换(EMT)的可塑性通过维持EMT和MET状态之间的转换,在肿瘤的进展和转移中起着关键作用。本研究目的是了